Loading...
Longboard Pharmaceuticals, Inc.
LBPH•NASDAQ
Healthcare
Biotechnology
$59.98
$0.00(0.00%)

Over the past four quarters, Longboard Pharmaceuticals, Inc. demonstrated steady revenue growth, increasing from $8000.00 in Q4 2023 to $0.00 in Q3 2024. Operating income reached -$28.12M in Q3 2024, maintaining a consistent N/A margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$28.12M, reflecting operational efficiency. Net income dropped to -$24.54M, with EPS at -$0.63. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan